Immune activation, immunosenescence, and osteoprotegerin as markers of endothelial dysfunction in subclinical hiv-associated atherosclerosis

Mediators of Inflammation

Volumn 2014, Issue , 2014, Pages

  D'Abramo, Alessandra ^a   Zingaropoli, Maria Antonella ^a   Oliva, Alessandra ^a   D'Agostino, Claudia ^a   Al Moghazi, Samir ^a   De Luca, Giulia ^a   Iannetta, Marco ^a   Mastroianni, Claudio Maria ^a   Vullo, Vincenzo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; INTERLEUKIN 6; OSTEOPROTEGERIN; BIOLOGICAL MARKER; IL6 PROTEIN, HUMAN; TNFRSF11B PROTEIN, HUMAN;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; ELISA KIT; ENDOTHELIAL DYSFUNCTION; FEMALE; FLOW CYTOMETRY; FRAMINGHAM RISK SCORE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PHENOTYPE; SENESCENCE; T LYMPHOCYTE; BLOOD; CASE CONTROL STUDY; CELL AGING; COMPLICATION; DISEASE COURSE; HIV INFECTIONS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MIDDLE AGED;

ADULT; ANTI-HIV AGENTS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CAROTID INTIMA-MEDIA THICKNESS; CASE-CONTROL STUDIES; CD8-POSITIVE T-LYMPHOCYTES; CELL AGING; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HUMANS; INTERLEUKIN-6; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; OSTEOPROTEGERIN;

EID: 84908347349     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2014/192594     Document Type: Article

References (40)

1. Jeong S. J., Kim H. W., Ku N. S., Han S. H., Kim C. O., Choi J. Y., Song Y. G., Kim J. M., Clinical factors associated with carotid plaque and intima-medial thickness in HIV-infected patients. Yonsei Medical Journal 2013 54 4 990 998 10.3349/ymj.2013.54.4.990 2-s2.0-84878215300
2. Hakeem A., Bhatti S., Cilingiroglu M., The spectrum of atherosclerotic coronary artery disease in HIV patients. Current Atherosclerosis Reports 2010 12 2 119 124 10.1007/s11883-010-0089-4 2-s2.0-77953534488
3. D'Ettorre G., Francone M., Mancone M., Ceccarelli G., Ascarelli A., Vullo F., Baroncelli S., Galluzzo M. C., Catalano C., Strano S., Fedele F., Mastroianni C., Palmisano L., Vullo V., Significant coronary stenosis detected by coronary computed angiography in asymptomatic HIV infected subjects. Journal of Infection 2012 64 1 82 88 10.1016/j.jinf.2011.09.007 2-s2.0-84455173658
4. Deeks S. G., HIV infection, inflammation, immunosenescence, and aging. Annual Review of Medicine 2011 62 141 155 10.1146/annurev-med-042909-093756
5. Brenchley J. M., Schacker T. W., Ruff L. E., Price D. A., Taylor J. H., Beilman G. J., Nguyen P. L., Khoruts A., Larson M., Haase A. T., Douek D. C., CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. Journal of Experimental Medicine 2004 200 6 749 759 10.1084/jem.20040874 2-s2.0-4644342929
6. Brenchley J. M., Price D. A., Schacker T. W., Asher T. E., Silvestri G., Rao S., Kazzaz Z., Bornstein E., Lambotte O., Altmann D., Blazar B. R., Rodriguez B., Teixeira-Johnson L., Landay A., Martin J. N., Hecht F. M., Picker L. J., Lederman M. M., Deeks S. G., Douek D. C., Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nature Medicine 2006 12 12 1365 1371 10.1038/nm1511 2-s2.0-33845532053
7. Le Saux S., Weyand C. M., Goronzy J. J., Mechanisms of immunosenescence: lessons from models of accelerated immune aging. Annals of the New York Academy of Sciences 2012 1247 1 69 82 10.1111/j.1749-6632.2011.06297.x 2-s2.0-84856449106
8. Coll B., Parra S., Alonso-Villaverde C., Aragonés G., Montero M., Camps J., Joven J., Masana L., The role of immunity and inflammation in the progression of atherosclerosis in patients with HIV infection. Stroke 2007 38 9 2477 2484 10.1161/STROKEAHA.106.479030 2-s2.0-34548222130
9. + patients on virologically effective cART with early atherosclerosis. PLoS ONE 2012 7 9 e46073 10.1371/journal.pone.0046073 2-s2.0-84866923510
10. Guzmán-Fulgencio M., Medrano J., Rallón N., Echeverria-Urabayen A., Miguel Benito J., Restrepo C., García-Álvarez M., Vispo E., San Roman J., Sánchez-Piedra C., Soriano V., Resino S., Soluble markers of inflammation are associated with Framingham scores in HIV-infected patients on suppressive antiretroviral therapy. Journal of Infection 2011 63 5 382 390 10.1016/j.jinf.2011.08.006 2-s2.0-80054078259
11. Biasillo G., Leo M., della Bona R., Biasucci L. M., Inflammatory biomarkers and coronary heart disease: from bench to bedside and back. Internal and Emergency Medicine 2010 5 3 225 233 10.1007/s11739-010-0361-1 2-s2.0-77953539467
12. Worm S. W., Hsue P., Role of biomarkers in predicting CVD risk in the setting of HIV infection? Current Opinion in HIV and AIDS 2010 5 6 467 472 10.1097/COH.0b013e32833f2ea6 2-s2.0-78049252684
13. D'Abramo A., D'Agostino C., Oliva A., Early atherosclerosis in HIV infected subjects on suppressive antiretroviral treatment: role of osteoprotegerin. ISRN AIDS 2013 2013 6 737083 10.1155/2013/737083
14. Hofbauer L. C., Schoppet M., Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. The Journal of the American Medical Association 2004 292 4 490 495 10.1001/jama.292.4.490 2-s2.0-3242781731
15. Ssinabulya I., Kayima J., Longenecker C., Luwedde M., Semitala F., Kambugu A., Ameda F., Bugeza S., McComsey G., Freers J., Nakanjako D., Subclinical atherosclerosis among HIV-infected adults attending HIV/AIDS care at two large ambulatory HIV clinics in Uganda. PLoS ONE 2014 9 2 e89537 10.1371/journal.pone.0089537 2-s2.0-84896519860
16. Lee C. J., Park S., The role of carotid ultrasound for cardiovascular risk stratification beyond traditional risk factors. Yonsei Medical Journal 2014 55 3 551 557 10.3349/ymj.2014.55.3.551 2-s2.0-84898738653
17. Kestens L., Vanham G., Gigase P., Young G., Hannet I., Vanlangendonck F., Hulstaert F., Bach B. A., Expression of activation antigens, HLA-DR and CD38, on CD8 lymphocytes during HIV-1 infection. AIDS 1992 6 8 793 797 10.1097/00002030-199208000-00004 2-s2.0-0026694144
18. Effros R. B., Loss of CD28 expression on T lymphocytes: a marker of replicative senescence. Developmental and Comparative Immunology 1997 21 6 471 478 10.1016/S0145-305X(97)00027-X 2-s2.0-0031472503
19. Mancia G., Fagard R., Narkiewicz K., 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. Journal of Hypertension 2013 31 10 1925 1938 10.1097/HJH.0b013e328364ca4c
20. Currier J. S., Update on cardiovascular complications in HIV infection. Topics in HIV Medicine 2009 17 3 98 103
21. Ferrando-Martínez S., Ruiz-Mateos E., Romero-Sánchez M. C., Muñoz-Fernández M. Á., Viciana P., Genebat M., Leal M., HIV infection-related premature immunosenescence: high rates of immune exhaustion after short time of infection. Current HIV Research 2011 9 5 289 294 10.2174/157016211797636008 2-s2.0-80053959928
22. Gamadia L. E., van Leeuwen E. M. M., Remmerswaal E. B. M., Yong S.-L., Surachno S., Wertheim-Van Dillen P. M. E., Ten Berge I. J. M., Van Lier R. A. W., The size and phenotype of virus-specific T cell populations is determined by repetitive antigenic stimulation and environmental cytokines. The Journal of Immunology 2004 172 10 6107 6114 10.4049/jimmunol.172.10.6107 2-s2.0-2442418917
23. Hakim F. T., Gress R. E., Immunosenescence: immune deficits in the elderly and therapeutic strategies to enhance immune competence. Expert Review of Clinical Immunology 2005 1 3 443 458
24. + T-cell differentiation towards senescence in HIV-1 infection. PLoS Biology 2004 2 2, article e20 10.1371/journal.pbio.0020020 2-s2.0-19344370239
25. + T cells in antiretroviral therapy-naive HIV-infected adults enrolled in adult clinical trials group studies. Journal of Infectious Diseases 2012 205 11 1730 1738 10.1093/infdis/jis260 2-s2.0-84861083813
26. Grunfeld C., Delaney J. A., Wanke C., Currier J. S., Scherzer R., Biggs M. L., Tien P. C., Shlipak M. G., Sidney S., Polak J. F., O'Leary D., Bacchetti P., Kronmal R. A., Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS 2009 23 14 1841 1849 10.1097/QAD.0b013e32832d3b85 2-s2.0-70249090072
27. Lichtner M., Cuomo M. R., Rossi R., Strano S., Massetti A. P., Mastroianni C. M., Vullo V., Increased carotid intima media thickness is associated with depletion of circulating myeloid dendritic cells in HIV-infected patients on suppressive antiretroviral treatment. Atherosclerosis 2009 204 2 e1 e3 10.1016/j.atherosclerosis.2008.12.025 2-s2.0-67349153088
28. Lorenz M. W., Stephan C., Harmjanz A., Staszewski S., Buehler A., Bickel M., von Kegler S., Ruhkamp D., Steinmetz H., Sitzer M., Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis. Atherosclerosis 2008 196 2 720 726 10.1016/j.atherosclerosis.2006.12.022 2-s2.0-38349193415
29. Melander O., Newton-Cheh C., Almgren P., Hedblad B., Berglund G., Engström G., Persson M., Smith J. G., Magnusson M., Christensson A., Struck J., Morgenthaler N. G., Bergmann A., Pencina M. J., Wang T. J., Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. The Journal of the American Medical Association 2009 302 1 49 57 10.1001/jama.2009.943 2-s2.0-67649992452
30. Ross A. C., Rizk N., O'Riordan M. A., Dogra V., El-Bejjani D., Storer N., Harrill D., Tungsiripat M., Adell J., McComsey G. A., Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clinical Infectious Diseases 2009 49 7 1119 1127 10.1086/605578 2-s2.0-70349923389
31. Metkus T. Jr., Brown T. T., Post W. S., Cardiovascular disease associated with the human immunodeficiency virus: an update. Current Treatment Options in Cardiovascular Medicine 2014 16 11 346 10.1007/s11936-014-0346-x
32. van Campenhout A., Golledge J., Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis 2009 204 2 321 329 10.1016/j.atherosclerosis.2008.09.033 2-s2.0-67349099856
33. Hwang J. J., Wei J., Abbara S., Grinspoon S. K., Lo J., Receptor activator of nuclear factor- B ligand (RANKL) and its relationship to coronary atherosclerosis in HIV patients. Journal of Acquired Immune Deficiency Syndromes 2012 61 3 359 363 10.1097/QAI.0b013e31826a6c16 2-s2.0-84872044689
34. Kiechl S., Werner P., Knoflach M., Furtner M., Willeit J., Schett G., The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. Expert Review of Cardiovascular Therapy 2006 4 6 801 811 10.1586/14779072.4.6.801 2-s2.0-33845898720
35. Boyce B. F., Xing L., Functions of RANKL/RANK/OPG in bone modeling and remodeling. Archives of Biochemistry and Biophysics 2008 473 2 139 146 10.1016/j.abb.2008.03.018 2-s2.0-42749083246
36. Reid P., Holen I., Pathophysiological roles of osteoprotegerin (OPG). European Journal of Cell Biology 2009 88 1 1 17 10.1016/j.ejcb.2008.06.004 2-s2.0-57249094356
37. Stejskal D., Bartek J., Pastorková R., Růžička V., Oral I., Horalík D., Osteoprotegerin, RANK, RANKL. Biomedical Papers 2001 145 2 61 64 10.5507/bp.2001.013 2-s2.0-0035754453
38. Wright H. L., McCarthy H. S., Middleton J., Marshall M. J., RANK, RANKL and osteoprotegerin in bone biology and disease. Current Reviews in Musculoskeletal Medicine 2009 2 1 56 64 10.1007/s12178-009-9046-7 2-s2.0-67349272085
39. Schoppet M., Sattler A. M., Schaefer J. R., Herzum M., Maisch B., Hofbauer L., Increased osteoprotegerin serum levels in men with coronary artery disease. The Journal of Clinical Endocrinology & Metabolism 2003 88 3 1024 1028 10.1210/jc.2002-020775 2-s2.0-0037338946
40. Vik A., Mathiesen E. B., Brox J., Wilsgaard T., Njølstad I., Jørgensen L., Hansen J.-B., Serum osteoprotegerin is a predictor for incident cardiovascular disease and mortality in a general population: the Tromsø study. Journal of Thrombosis and Haemostasis 2011 9 4 638 644 10.1111/j.1538-7836.2011.04222.x 2-s2.0-79953305288